ARS Pharmaceuticals, Inc (SPRY) - Total Assets
Based on the latest financial reports, ARS Pharmaceuticals, Inc (SPRY) holds total assets worth $327.65 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore ARS Pharmaceuticals, Inc (SPRY) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
ARS Pharmaceuticals, Inc - Total Assets Trend (2018–2025)
This chart illustrates how ARS Pharmaceuticals, Inc's total assets have evolved over time, based on quarterly financial data. See ARS Pharmaceuticals, Inc shareholders equity for net asset value and shareholders' equity analysis.
ARS Pharmaceuticals, Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
ARS Pharmaceuticals, Inc's total assets of $327.65 Million consist of 87.0% current assets and 13.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 12.6% |
| Accounts Receivable | $25.35 Million | 7.7% |
| Inventory | $8.37 Million | 2.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $14.45 Million | 4.4% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how ARS Pharmaceuticals, Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ARS Pharmaceuticals, Inc (SPRY) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ARS Pharmaceuticals, Inc's current assets represent 87.0% of total assets in 2025, an increase from 75.4% in 2018.
- Cash Position: Cash and equivalents constituted 12.6% of total assets in 2025, down from 73.2% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 7.7% of total assets.
ARS Pharmaceuticals, Inc Competitors by Total Assets
Key competitors of ARS Pharmaceuticals, Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Genfit S.A.
PA:GNFT
|
France | €157.93 Million |
|
Hyundai Bioscience Co. Ltd
KQ:048410
|
Korea | ₩129.10 Billion |
|
Altimmune Inc
NASDAQ:ALT
|
USA | $279.93 Million |
|
Clarity Pharmaceuticals Ltd
AU:CU6
|
Australia | AU$255.67 Million |
|
Jiangsu GDK Biotechnology Co Ltd
SHG:688670
|
China | CN¥1.48 Billion |
ARS Pharmaceuticals, Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.28 | 14.26 | 32.63 |
| Quick Ratio | 7.06 | 14.04 | 32.63 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $245.75 Million | $310.86 Million | $366.75 Million |
ARS Pharmaceuticals, Inc - Advanced Valuation Insights
This section examines the relationship between ARS Pharmaceuticals, Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.60 |
| Latest Market Cap to Assets Ratio | 1.93 |
| Asset Growth Rate (YoY) | -6.7% |
| Total Assets | $327.65 Million |
| Market Capitalization | $631.55 Million USD |
Valuation Analysis
Above Book Valuation: The market values ARS Pharmaceuticals, Inc's assets above their book value (1.93x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: ARS Pharmaceuticals, Inc's assets decreased by 6.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for ARS Pharmaceuticals, Inc (2018–2025)
The table below shows the annual total assets of ARS Pharmaceuticals, Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $327.65 Million | -6.69% |
| 2024-12-31 | $351.15 Million | +50.59% |
| 2023-12-31 | $233.19 Million | -17.14% |
| 2022-12-31 | $281.44 Million | +358.02% |
| 2021-12-31 | $61.45 Million | +132.69% |
| 2020-12-31 | $26.41 Million | +68.77% |
| 2019-12-31 | $15.65 Million | -43.20% |
| 2018-12-31 | $27.55 Million | -- |
About ARS Pharmaceuticals, Inc
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is … Read more